Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Royalty Pharma owns a diversified stream of royalty income. It’s run by...
— Christina Siegel Malbon
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Royalty Pharma plc
More institutional theses from Patient Capital Management
The manager believes Kosmos Energy's intrinsic value is three times its current market price, driven by a looming inflection in free cash flow. As capital expenditures...
Precigen is an undervalued cell and gene therapy company poised for its first FDA approval later this year. A recent private...
The fund initiated a position in the Bitcoin ETF, believing the digital asset is still in the early stages of its adoption lifecycle. Despite its recent...